- Home
- CGEM vs OI Comparison
CGEM vs OI Comparison
Compare CGEM & OI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | OI |
|---|---|---|
| Founded | 2016 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CGEM | OI |
|---|---|---|
| Price | $17.59 | $7.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $30.13 | $15.29 |
| AVG Volume (30 Days) | 522.7K | ★ 4.0M |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,426,000,000.00 |
| Revenue This Year | N/A | $2.77 |
| Revenue Next Year | $5.20 | $1.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $7.01 |
| 52 Week High | $19.43 | $16.91 |
Technical Indicators
Market Signals| Indicator | CGEM | OI |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 32.24 |
| Support Level | $17.19 | N/A |
| Resistance Level | $19.10 | $9.63 |
| Average True Range (ATR) | 0.89 | 0.38 |
| MACD | -0.05 | -0.18 |
| Stochastic Oscillator | 81.78 | 3.58 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About OI O-I Glass Inc.
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.